Canada’s Drug Agency Backs EMPAVELI For Rare Kidney Diseases C3G And IC-MPGN
WALTHAM, Mass., July 09, 2026 – Canada’s Drug Agency (CDA) has issued a positive reimbursement recommendation, with conditions, for EMPAVELI® (pegcetacoplan) in the treatment of C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), Swedish Orphan Biovitrum AB (Sobi) announced. The recommendation covers patients aged 12 and older and applies specifically to reducing proteinuria in … Read more
